Who is this joint-care site for?

What will you find here?

A joint may ache after more walking or lifting. Wear inside the joint can add soreness too. Rest may calm that ache.

Fever, fast swelling, or a major injury is different. Those symptoms need medical help. They don't belong in a routine clinic visit.

What does QC Kinetix offer?

QC Kinetix may discuss regenerative treatments, its term for office care using a blood draw or marrow draw. The medical provider examines your joint first. That person explains the procedure and likely soreness afterward.

PRP is the clinic's short name for platelet-rich plasma. Your blood is spun to gather platelets before plasma goes into the joint. Concentrated PRP calls for related drawing and spinning steps.

Joint preservation means discussing choices before knee or hip surgery. Ask which exact procedure is offered. You won't get the same answer as every patient.

Who runs this site?

The footer tells you who operates this site. It also says those clinic owners benefit from bookings. Keep that fact in mind when reading clinic offers.

The health copy gives general facts, not personal advice. You can ask your own doctor for another view. That's wise when the diagnosis or procedure isn't clear.

What can't this site decide?

This page can't examine your joint or know your history. It can't tell you to stop medicine. Those decisions need a doctor who knows you.

It can't handle an emergency either. A hot joint with fever needs quick care. Go to a hospital when your symptoms are severe.

Sources

1. A CDC public health investigation confirmed culture-positive bacterial infections in 20 patients who received umbilical cord blood-derived products marketed as stem cell treatment between August 2017 and September 2018; whole-genome sequencing matched patient isolates to the product.

   Hartnett KP, et al. — Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies. JAMA Netw Open, 2021. DOI: 10.1001/jamanetworkopen.2021.28615.

2. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.

3. Three patients who received intravitreal injections of autologous adipose-derived 'stem cells' at a US clinic for macular degeneration suffered severe bilateral vision loss; pre-injection acuity ranged from 20/30 to 20/200 and one year later ranged from 20/200 to no light perception.

   Kuriyan AE, et al. — Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD. N Engl J Med, 2017. DOI: 10.1056/NEJMoa1609583.

4. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

5. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

6. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.